Clinical Trials
AdarX
A Phase 2, Randomized, Masked, Placebo-Controlled Study of Subcutaneously Administered ADX-038 in Participants with Geographic Atrophy (GA) Secondary to Age Related Macular Degeneration (AMD).
Overview
ADX-038 is a new type of treatment known as small interfering RNA (siRNA) therapy.
siRNA works like a tiny “messenger blocker” and in this case, ADX-038 is designed to block the body from making a protein called complement factor B (CFB), which plays a role in causing ongoing inflammation in eye diseases like GA.
By lowering CFB levels, ADX-038 may help calm the inflammation, protect the retina, and possibly slow down further vision loss.
However, because this protein also helps protect against infections, blocking it may increase your risk of certain serious infections.
This study will assess the efficacy and safety of ADX-038 for the treatment of GA.
In this study, there will be 2 treatment groups.
The 2 treatment groups are:
• ADX-038 400mg
• Placebo
You will have a 1 in 2 chance (50%) of receiving ADX-038 and a 1 in 2 chance (50%) of receiving placebo.
A placebo is a medication with no active ingredients, or a procedure without any medical benefit.
It looks like the real thing but is not.
ADX-038 will be administered as a subcutaneous injection every 3 months for the first year of the study.
The study duration is 28 months.
For further information please contact Cerulea on 99298076 or info@ceruleaclinicaltrials.org.au
- Principal Investigator
Professor Robyn Guymer
ADX-038 is a new type of treatment known as small interfering RNA (siRNA) therapy.
siRNA works like a tiny “messenger blocker” and in this case, ADX-038 is designed to block the body from making a protein called complement factor B (CFB), which plays a role in causing ongoing inflammation in eye diseases like GA.
By lowering CFB levels, ADX-038 may help calm the inflammation, protect the retina, and possibly slow down further vision loss.
However, because this protein also helps protect against infections, blocking it may increase your risk of certain serious infections.
This study will assess the efficacy and safety of ADX-038 for the treatment of GA.
In this study, there will be 2 treatment groups.
The 2 treatment groups are:
• ADX-038 400mg
• Placebo
You will have a 1 in 2 chance (50%) of receiving ADX-038 and a 1 in 2 chance (50%) of receiving placebo.
A placebo is a medication with no active ingredients, or a procedure without any medical benefit.
It looks like the real thing but is not.
ADX-038 will be administered as a subcutaneous injection every 3 months for the first year of the study.
The study duration is 28 months.
For further information please contact Cerulea on 99298076 or info@ceruleaclinicaltrials.org.au
- Principal Investigator